Max-delbrueck-centrum Fuer Molekulare Medizin

Charite - Universitaetsmedizin Berlin

Max-delbruck-centrum Fur Molekulare Medizin

Berlin Cures Gmbh

Charite—universtatsmedizin Berlin

Max-delbruck-centrum Fur Molekular Medizin

Charité – Universitätsmedizin Berlin

Annekathrin Haberland

Gerd Wallukat

Ingolf Schimke

Johannes Müller

Katrin Wenzel

Michael Böttger

Regins Reszka

Peter Göttel

Andreas Kage

Claudia Dahmen

The present invention relates to new aptamer molecules for use in therapy of a subject by inhibiting or suppressing the activation of TLR9 in a cell, a method of inhibiting or suppressing the activation of TLR9 in a cell using such aptamer molecules, a pharmaceutical composition and a kit comprising such aptamer molecules and the use of aptamer molecules for inhibiting or suppressing TLR9 activation.

Aptamers for use in inhibition and/or suppression of TLR9 activation

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclampsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.

Use of aptamers in therapy and/or diagnosis of autoimmune diseases

The present invention is directed to an aptamer comprising or consisting of the nucleic acid sequence of SEQ ID No. 1, SEQ ID No. 2, SEQ ID No. 3 and/or a nucleic acid sequence being at least 80% identical to one of SEQ ID No. 1, 2 and 3 for use in therapy and/or diagnosis of autoimmune diseases, wherein the autoimmune disease is cardiomyopathy, dilated cardiomyopathy (DCM), peripartum cardiomyopathy (PPCM), idiopathic cardiomyopathy, Chagas' cardiomyopathy, Chagas' megacolon, Chagas' megaesophagus, Chagas' neuropathy, benign prostatic hyperplasia, scleroderma, psoriasis, Raynaud syndrome, pre-eclamsia, kidney allograft rejection, myocarditis, glaucoma, hypertension, pulmonary hypertension, malignant hypertension, and/or Alzheimer's disease.

The invention relates to a method for improving transfection efficiency through the use of K16-peptides. In addition, the invention further relates to novel K16-peptides, including a K16-CYC peptide.

Method for improving transfection efficiency

Growing community of inventors

Berlin, Germany

Annekathrin Haberland